|Bid||18.00 x 800|
|Ask||21.88 x 800|
|Day's Range||18.17 - 18.93|
|52 Week Range||17.22 - 21.96|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
SANTA CLARA, Calif. , Nov. 7, 2018 /PRNewswire/ -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that is pioneering the minimally invasive surgical treatment of the sacroiliac joint with the iFuse ...
Nearly half of the 22 U.S. IPOs in October priced below their range, according to Renaissance Capital, which manages exchange-traded funds made up of IPO stocks. Several more were postponed.
SANTA CLARA, Calif. , Oct. 19, 2018 /PRNewswire/ -- SI-BONE, Inc. (Nasdaq: SIBN) ("SI-BONE"), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac ...
Medical device company SI-Bone, Inc. is set to begin trading on the Nasdaq Global Market under the ticker symbol “SIBN.” The Company SI-Bone has pioneered a minimally invasive surgical implant system ...
After 15 U.S. venture-backed life-sciences initial public offerings roared out of the gate in the third quarter, another crop looks poised to close out the year on a high note. The 15 biotech deals to go out in the third quarter was triple the size of last year’s class in the same time frame, and they bring the 2018 total of biopharma IPOs to 41, according to Dow Jones VentureSource. Inc., accounted for six of the top 10 largest U.S. venture-backed IPOs for the quarter.
SANTA CLARA, Calif. , Oct. 16, 2018 /PRNewswire/ -- SI-BONE, Inc. (Nasdaq: SIBN) ("SI-BONE"), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . PhaseBio Pharmaceuticals Inc (PHAS) will issue 5 million shares between $12 and $14 Thursday on the Nasdaq. Based in Pennsylvania, ...